<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859976</url>
  </required_header>
  <id_info>
    <org_study_id>BMETEU.CR.EU27</org_study_id>
    <secondary_id>UK REC Ref: 08/H0724/24</secondary_id>
    <nct_id>NCT00859976</nct_id>
  </id_info>
  <brief_title>Study Comparing BoneMaster Hydroxyapatite Coating With Plasma-sprayed Hydroxyapatite Coating on Acetabular Cups</brief_title>
  <official_title>Prospective Randomised Control Trial to Compare the Effect Upon Bone Density and Clinical Outcomes When Using BoneMaster HA Coated Acetabular Cups Compared With Plasma Sprayed HA Coated Cups in Patients With Total Hip Replacements</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomised controlled trial will be carried out on patients that require a total hip
      replacement (THR) to reduce pain and restore their function. One way of fixing the hip joint
      to the bone is by coating the implant to encourage the body to grow bone onto the replacement
      hip. This study is aiming to find out whether the new (Bonemaster) coating allows increased
      bony growth onto the cup when compared to the usual (plasma-sprayed) coating. This may reduce
      the incidence of early failures due to poor bony attachment, which is a well known
      complication for early failure of total hip replacements.

      The study will compare two different types of coating (BoneMaster and Plasma-sprayed) on the
      cup of the replacement hip. Density of the bone immediately surrounding the cup will be
      observed to see if there are differences between the two groups. The density of bone will be
      measured using standard x−ray assessment and in a smaller sample of 14 patients, using a
      special scan called Dual Energy X−ray Absorptiometry (DEXA Scan). Functional comparisons will
      be assessed through clinical scores.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be identified by the orthopaedic surgeon in the orthopaedic clinic and
      deemed suitable for the study if all inclusion and exclusion criteria are met. 210 patients
      will be recruited to the study and each patient will be randomised into either of the groups
      allowing 105 patients into each group. Patients will be followed up at 6 months, 1 year and 2
      years after the surgery. All patients will have radiographic assessments at these follow-up
      intervals, as well as Harris Hip, Oxford Hip and Womac scores. This will allow comparison of
      the two groups.

      The BoneMaster coating has been extensively tested in cell and animal studies and has been
      evaluated in one previous clinical study and showed favorable results. Further investigation
      is required to ensure the new coating may enhance bony growth allowing better fixation of the
      hips in the early period after the operation and also over a longer period of time. The
      growth needs to be measured using a more sensitive scan than radiographic assessment alone,
      called DEXA which was also used in the previous study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Record and Measure Bone Density Using DEXA Scans at 24 Months.</measure>
    <time_frame>2 years.</time_frame>
    <description>DEXA scan cohort - DEXA scan was used to measure bone density. Below is the calculated net average bone mineral density (BMD) percentage change from baseline at 2 years.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiography to Determine Radiolucency in All Three DeLee &amp; Charnley Zones of the Acetabulum.</measure>
    <time_frame>2 years.</time_frame>
    <description>34 patient cases without duplicated data were the basis for the radiographic analysis that was conducted: Bonemaster group, n = 12; Plasma-Sprayed group, n = 22. The degree of osseous-fixation was determined by grading: 1-2 mm radiolucencies, classed as not fixated; &gt;2mm radiolucencies, classed as unstable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes Are Functional Assessment Using Harris Hip Score</measure>
    <time_frame>2 years</time_frame>
    <description>Modified Harris Hip Score, total score 0-100. A score of &lt;70 is poor, 70-79 is fair, 80-89 is good, 90-100 is excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes Are Clinical Assessment Using Oxford Hip Score</measure>
    <time_frame>2 years.</time_frame>
    <description>Oxford Hip Score, scored 12-60. The Oxford hip score - this score was based on the original publication where each answer gives a score of 1-5. A score of 1 for each question, represented best outcome/least symptoms. Therefore a total score of 12 was the best overall outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcomes Are Clinical Assessment Using WOMAC Hip Score</measure>
    <time_frame>2 years</time_frame>
    <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Hip Score, Each question is scored on a scale of 0 (best health state) to 4 (worst health state); total WOMAC hip score, 0 being the best and 96 being the worst.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">167</enrollment>
  <condition>Arthropathy of Hip</condition>
  <arm_group>
    <arm_group_label>Plasma-sprayed shell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BoneMaster coated shell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BoneMaster coated acetabular shell.</intervention_name>
    <description>Bonemaster coated Exceed Acetabular Shell</description>
    <arm_group_label>BoneMaster coated shell</arm_group_label>
    <other_name>Bonemaster coated Exceed Acetabular Shell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasma Coated Acetabular Shell</intervention_name>
    <description>Plasma HA coated Exceed Acetabular Shell</description>
    <arm_group_label>Plasma-sprayed shell</arm_group_label>
    <other_name>Plasma Hydroxyapatite coated Exceed Acetabular Shell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients suitable for THR surgery with a diagnosis of Osteoarthritis

          -  Patients aged 40 -85 years old.

          -  Patients with limited co-morbidity - ASA I - III (low risk for surgery)

          -  Patients must be able to understand instructions and be willing to return for follow
             up

        Exclusion Criteria

          -  Rheumatoid arthritis

          -  Patients requiring supplemental screw fixation

          -  Previous hip surgery to the affected hip

          -  Patients with significant co-morbidity - ASA IV - V (high risk for surgery)

          -  Dementia

          -  Neurological conditions affecting everyday functional ability and hip movement

          -  The patient is unable to give informed consent

          -  Patients who have suffered from cancer

          -  The patient is currently part of another research study

          -  Patients who need to take Non Steroidal Anti-inflammatory Drugs (NSAIDs) in the first
             6 weeks after surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helmut ZAHN</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Harvey Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Harvey Hospital</name>
      <address>
        <city>Ashford</city>
        <state>Kent</state>
        <zip>TN24 0LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2009</study_first_posted>
  <results_first_submitted>June 19, 2017</results_first_submitted>
  <results_first_submitted_qc>September 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2019</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BoneMaster</keyword>
  <keyword>Total Hip Replacement</keyword>
  <keyword>Bone Density</keyword>
  <keyword>Patients suitable for Total Hip Replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Plasma-sprayed Shell</title>
          <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
        </group>
        <group group_id="P2">
          <title>BoneMaster Coated Shell</title>
          <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plasma-sprayed Shell</title>
          <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
        </group>
        <group group_id="B2">
          <title>BoneMaster Coated Shell</title>
          <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="82"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="167"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="7"/>
                    <measurement group_id="B2" value="70" spread="9"/>
                    <measurement group_id="B3" value="68.55" spread="8.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Record and Measure Bone Density Using DEXA Scans at 24 Months.</title>
        <description>DEXA scan cohort - DEXA scan was used to measure bone density. Below is the calculated net average bone mineral density (BMD) percentage change from baseline at 2 years.</description>
        <time_frame>2 years.</time_frame>
        <population>DEXA scan cohort: Bonemaster group, n = 7; Plasma-Sprayed group, n = 7</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma-sprayed Shell</title>
            <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
          </group>
          <group group_id="O2">
            <title>BoneMaster Coated Shell</title>
            <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Record and Measure Bone Density Using DEXA Scans at 24 Months.</title>
          <description>DEXA scan cohort - DEXA scan was used to measure bone density. Below is the calculated net average bone mineral density (BMD) percentage change from baseline at 2 years.</description>
          <population>DEXA scan cohort: Bonemaster group, n = 7; Plasma-Sprayed group, n = 7</population>
          <units>Net average BMD %change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.0" spread="4.0"/>
                    <measurement group_id="O2" value="5.7" spread="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>A superiority test was used to calculate the number of patients that are needed in order to show a difference between the bone mineral density surrounding BoneMaster coated cups compared to plasma HA sprayed cups.</non_inferiority_desc>
            <p_value>0.4570</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Change in bone mineral density, normalised to baseline levels.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcomes Are Functional Assessment Using Harris Hip Score</title>
        <description>Modified Harris Hip Score, total score 0-100. A score of &lt;70 is poor, 70-79 is fair, 80-89 is good, 90-100 is excellent.</description>
        <time_frame>2 years</time_frame>
        <population>2 years post-op</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma-sprayed Shell</title>
            <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
          </group>
          <group group_id="O2">
            <title>BoneMaster Coated Shell</title>
            <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcomes Are Functional Assessment Using Harris Hip Score</title>
          <description>Modified Harris Hip Score, total score 0-100. A score of &lt;70 is poor, 70-79 is fair, 80-89 is good, 90-100 is excellent.</description>
          <population>2 years post-op</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.92" spread="15.82"/>
                    <measurement group_id="O2" value="81.83" spread="20.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcomes Are Clinical Assessment Using Oxford Hip Score</title>
        <description>Oxford Hip Score, scored 12-60. The Oxford hip score - this score was based on the original publication where each answer gives a score of 1-5. A score of 1 for each question, represented best outcome/least symptoms. Therefore a total score of 12 was the best overall outcome.</description>
        <time_frame>2 years.</time_frame>
        <population>2 years post-op</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma-sprayed Shell</title>
            <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
          </group>
          <group group_id="O2">
            <title>BoneMaster Coated Shell</title>
            <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcomes Are Clinical Assessment Using Oxford Hip Score</title>
          <description>Oxford Hip Score, scored 12-60. The Oxford hip score - this score was based on the original publication where each answer gives a score of 1-5. A score of 1 for each question, represented best outcome/least symptoms. Therefore a total score of 12 was the best overall outcome.</description>
          <population>2 years post-op</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2" spread="8"/>
                    <measurement group_id="O2" value="19.8" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcomes Are Clinical Assessment Using WOMAC Hip Score</title>
        <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Hip Score, Each question is scored on a scale of 0 (best health state) to 4 (worst health state); total WOMAC hip score, 0 being the best and 96 being the worst.</description>
        <time_frame>2 years</time_frame>
        <population>2 years post-op</population>
        <group_list>
          <group group_id="O1">
            <title>Plasma-sprayed Shell</title>
            <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
          </group>
          <group group_id="O2">
            <title>BoneMaster Coated Shell</title>
            <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcomes Are Clinical Assessment Using WOMAC Hip Score</title>
          <description>Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Hip Score, Each question is scored on a scale of 0 (best health state) to 4 (worst health state); total WOMAC hip score, 0 being the best and 96 being the worst.</description>
          <population>2 years post-op</population>
          <units>Units on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="16.5"/>
                    <measurement group_id="O2" value="12.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Radiography to Determine Radiolucency in All Three DeLee &amp; Charnley Zones of the Acetabulum.</title>
        <description>34 patient cases without duplicated data were the basis for the radiographic analysis that was conducted: Bonemaster group, n = 12; Plasma-Sprayed group, n = 22. The degree of osseous-fixation was determined by grading: 1-2 mm radiolucencies, classed as not fixated; &gt;2mm radiolucencies, classed as unstable.</description>
        <time_frame>2 years.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Plasma-sprayed Shell</title>
            <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
          </group>
          <group group_id="O2">
            <title>BoneMaster Coated Shell</title>
            <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
          </group>
        </group_list>
        <measure>
          <title>Radiography to Determine Radiolucency in All Three DeLee &amp; Charnley Zones of the Acetabulum.</title>
          <description>34 patient cases without duplicated data were the basis for the radiographic analysis that was conducted: Bonemaster group, n = 12; Plasma-Sprayed group, n = 22. The degree of osseous-fixation was determined by grading: 1-2 mm radiolucencies, classed as not fixated; &gt;2mm radiolucencies, classed as unstable.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-2 mm radiolucency in Zone B1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 mm radiolucency in zone B2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Plasma-sprayed Shell</title>
          <description>Exceed ABT plasma-sprayed hydroxyapatite coated acetabular cup.
Plasma Coated Acetabular Shell: Plasma HA coated Exceed Acetabular Shell</description>
        </group>
        <group group_id="E2">
          <title>BoneMaster Coated Shell</title>
          <description>Exceed ABT BoneMaster hydroxyapatite coated acetabular cup.
BoneMaster coated acetabular shell.: Bonemaster coated Exceed Acetabular Shell</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Patient Deaths that were reported over the course of the study; considered SAE</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>2 units of blood given post-op</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular - stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall - patient confused</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Antibiotics given imm post-op</sub_title>
                <description>Unknown if this was related to infection or other condition. No further information available.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fall - soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Non-traumatic bruising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fractured pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Stomach cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urogenital adverse event with diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urogenital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory problems post-op; has COPD</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Needs scar revised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Lead</name_or_title>
      <organization>Zimmer Biomet</organization>
      <email>Maggie.Shen@zimmerbiomet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

